Prosecution Insights
Last updated: April 19, 2026
Application No. 17/451,109

SKIN CLARIFIER

Non-Final OA §101
Filed
Oct 15, 2021
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Johnson Consulting LLC
OA Round
5 (Non-Final)
54%
Grant Probability
Moderate
5-6
OA Rounds
3y 0m
To Grant
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
572 granted / 1058 resolved
-5.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
1125
Total Applications
across all art units

Statute-Specific Performance

§101
9.5%
-30.5% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1058 resolved cases

Office Action

§101
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 2, 2025 has been entered. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior Office action. Any rejection set forth in a previous Office action that is not specifically set forth below is withdrawn. 3. Claims 1-13 and 15-20 are pending. 4. In the reply filed on January 6, 2023, applicant elected the combination of lobelia herb powder, plantain leaf powder, and mullein leaf powder without traverse. 5. Claims 1-8, 16, 17, 19, and 20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Claim 17 is now withdrawn because would be allowable if limited to the elected species. However, claim 17 depends from claim 9 which is not allowable and also contains species that have not been examined. Claims 19 and 20 are withdrawn because the do not require all three of the elected species. The search has not been extended to encompass the non-elected species; thus, these claims are withdrawn until such time. 6. Claims 9-13, 15, and 18 are examined on the merits solely in regards to the elected species. Claim Rejections - 35 USC § 101 7. Claims 9-13, 15, and 18 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural product without significantly more. MPEP § 2106 sets forth the Subject Matter Eligibility Test to determine if a claim is directed to patent eligible subject matter. Step 1 asks if a claim is directed to a statutory category of invention. Applicant’s claims are directed to a product; thus, the answer to Step 1 is Yes. The analysis then moves to Step 2A, Prong One, which asks if a claim recites to a product of nature. In this case, applicant’s claims recite lobelia herb powder, plantain leaf powder, and mullein leaf powder. Lobelia, plantain, and mullein are all naturally occurring plants. Thus, the claims do recite products of nature. MPEP § 2106.04(b) states that “When a claim recites a nature-based product limitation, examiners should use the markedly different characteristics analysis discussed in MPEP § 2106.04(c) to evaluate the nature-based product limitation and determine the answer to Step 2A.” MPEP § 2106.04(c)(I) states that “if the nature-based product limitation is not naturally occurring, for example due to some human intervention, then the markedly different characteristics analysis must be performed to determine whether the claimed product limitation is a product of nature exception…”. To perform the markedly different characteristic analysis, MPEP § 2106.04(c)(II) states “The markedly different characteristics analysis compares the nature-based product limitation to its naturally occurring counterpart in its natural state. Markedly different characteristics can be expressed as the product’s structure, function, and/or other properties…”. In this case, there is no indication that mixing the specified ingredients together as commensurate in scope with the stated claims changes the structure, function, or other properties of the powdered plants in any marked way in comparison with the closest naturally occurring counterpart. The closest naturally occurring counterpart for each of the powdered plants is the plant itself. Each plant ingredient appears to maintain its naturally occurring structure and properties and is merely present in the combination. There is nothing to show that mixing the ingredients in together produces any sort of marked distinction. Thus, the claimed mixture as a whole does not display markedly different characteristics in comparison with the naturally occurring counterparts. Therefore, the answer to Step 2A, Prong One, is Yes. Thus, the analysis must move to Step 2A, Prong Two, which asks if the claim recites additional elements that integrate the judicial exception into a practical application. As discussed in MPEP § 2106.04(d)(2) this evaluation is performed by identifying whether there are additional elements recited in the claim beyond the judicial exception and evaluating these additional elements to determine whether the claim as a whole integrates the exception into a practical application. In this case, applicant’s claims are directed to a composition with an intended use of an oral medication for clarifying the skin and functioning as an anti-inflammatory agent. MPEP § 2106.04(d)(2) specifically states that a claim is only directed to “an intended use of a claimed invention or a field of use limitation, then it cannot integrate a judicial exception under the ‘treatment or prophylaxis’ consideration.” Therefore, applicant’s intended use is not sufficient to integrate the judicial exception into a practical application. Thus, the answer to Step 2A, Prong Two, is No. Thus, the analysis must move to Step 2B which asks if claims recite additional elements that amount to significantly more than the judicial exception. MPEP § 2106.05 states that this evaluation is performed by “Evaluating additional elements to determine whether they amount to an inventive concept requires considering them both individually and in combination to ensure that they amount to significantly more than the judicial exception itself.” In this case, the additional element in the claims is the combination of the ingredients. However, MPEP § 2106.05(d) states that well-understood, routine, and conventional activities are not sufficient to show that the claims amount to significantly more than the judicial exception. Mixing specific ingredients does not amount to significantly more than a combination of judicial exception because mixing compounds is well-understood, routine, and conventional in the field. Thus, mixing the ingredients together does not amount to significantly more than a combination of judicial exception because mixing compounds is well-understood, routine, and conventional in the field. In addition, applicant’s intended use of skin clarifying and anti-inflammation is not considered to amount to significantly more. As discussed in MPEP § 2106.05(I)(A), “Generally linking the use of the judicial exception to a particular technological environment or field of use” is not considered to be enough to qualify as significantly more. An intended use of a claimed composition only generally links the exception to the field of use. Therefore, the additional elements are not considered to amount to significantly more. Thus, the answer to Step 2B is No. Consequently, the claims are not directed to patent eligible subject matter. Response to Arguments Applicant's arguments filed Septebmer 2, 2025 have been fully considered but they are not persuasive. Applicant argues: Applicant contends that the claim defines a structurally novel composition. The claims recites a specific physical composition with a structure that does not exist in nature. The Examiner's rejection fails to appreciate the dispositive weight of the claim's structural limitations that at least two components are provided in the oral supplement in substantially equal proportions by weight. This is a precise, quantitative, and entirely artificial structural arrangement. Nature does not produce a mixture of lobelia, plantain leaf, or any of the other claimed powders in a 1:1 ratio ("substantially equal proportions by weight). This specific formulation is the "markedly different characteristic" (that the Examiner alleges the Applicant has not provided) from the components as they are found in nature. The Examiner's reasoning is analogous to saying because copper and tin are both naturally occurring elements, a claim to a random rock containing both copper and tin would be a natural product. Applicant would agree. But a claim to a bronze alloy comprising a specific ratio of copper and tin is patentable because that precise ratio creates a new material with new structural properties (hardness, melting point, etc.). The claim to a 1:1 ratio of specific plant powders in Applicant's claims is analogous in that it defines a new composition with a structure not found in nature… …This language requires that the final, formulated composition actually possesses the ability to activate D1 receptors. This functional property is a direct result of the specific, man-made combination and ratio of ingredients Applicant has selected for this oral supplement… …Applicant is not merely claiming a pile of herbs and hoping it has an effect. Applicant is claiming a specifically engineered composition that, due to its unnatural structure (the 1:1 ratio and specific combination), exhibits a particular functional property (D1 activation). This functional attribute is an inherent characteristic of the specific formulation as claimed (not the naturally occurring plant), thereby distinguishing it from a simple mixture of the individual components. This ties the unnatural structure (the specific 1:1 ratio) to an unnatural function (the targeted D1 activation). The Examiner cannot properly disregard these limitations as mere intended use - it is a defining property of the matter being claimed. The Office Action further alleges "applicant has not provided any evidence to support the assertions regarding "lobelia toxicity" and the claimed invention's ability to overcome this toxicity" and "applicant has not provided any evidence to support the assertions regarding the side effects associated with plantain leaf ingestion and the claimed invention's ability to overcome these side effects." Applicant uses less than a toxic level of each ingredient because the claims combine multiple different ingredients together that can achieve the same goal. Each ingredient amount was able to be reduced to below a toxic level due to the synergistic effects of the 2-3 in combination. Applicant has made such statements of record. However, the analysis is not whether or not the product is found in nature, the analysis is whether or not a combination of naturally occurring products produces a combination with markedly distinct characteristics. As discussed above, and in the previous Office actions, there is not considered to be sufficient evidence to show that the claimed combination of ingredients produces a composition with a markedly distinct characteristic. Applicant’s claims are similar in fact pattern to Nature-Based Product example number 1 issued by the USPTO (see https://www.uspto.gov/sites/default/files/documents/101_examples_1to36.pdf). This example has a mixture of three naturally occurring powders. The example states: …there is no naturally occurring counterpart to the claimed combination (the components do not occur together in nature), so the combination is compared to the individual components as they occur in nature. None of the three claimed substances are explosive in nature. When the substances are finely-ground and intimately mixed in the claimed ratio, however, the claimed combination is explosive upon ignition. This explosive property of the claimed combination is markedly different from the non-explosive properties of the substances by themselves in nature. Accordingly, the claimed combination has markedly different characteristics, and is not a “product of nature” exception. Thus, the claim is not directed to an exception (Step 2A: NO), and qualifies as eligible subject matter. Thus, this example shows that when a nature based product does not occur in nature (as with applicant’s claims), each component must be compared to the individual component as they occur in nature to determine if the combination is markedly distinct. In the example, the product was found eligible because there was evidence that showed while each individually was not explosive, the combination of the three component was explosive. However, in the current application, applicant has not provided any specific evidence to support the various assertions that the combination of the three ingredients is markedly distinct from the individual ingredients. Applicant has not shown results for the combination in comparison with the individual ingredients. This comparison is needed in order to determine if the combination actually produces a markedly distinct characteristic. 8. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Oct 15, 2021
Application Filed
Jan 23, 2023
Non-Final Rejection — §101
Apr 11, 2023
Interview Requested
Apr 20, 2023
Examiner Interview Summary
Apr 20, 2023
Applicant Interview (Telephonic)
Jun 13, 2023
Response Filed
Aug 24, 2023
Final Rejection — §101
Feb 12, 2024
Interview Requested
Feb 21, 2024
Applicant Interview (Telephonic)
Feb 21, 2024
Examiner Interview Summary
Feb 26, 2024
Request for Continued Examination
Mar 02, 2024
Response after Non-Final Action
Jun 06, 2024
Non-Final Rejection — §101
Dec 10, 2024
Response Filed
Mar 03, 2025
Final Rejection — §101
Sep 02, 2025
Request for Continued Examination
Sep 08, 2025
Response after Non-Final Action
Mar 26, 2026
Non-Final Rejection — §101
Apr 14, 2026
Examiner Interview Summary
Apr 14, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594313
COMPOSITION FOR RELIEVING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS COMPRISING A MIXED EXTRACT OF HOP AND CYNANCHUM WILFORDII AND METHOD FOR TREATING OR ALLEVIATING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS USING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12582674
Methods and Treatment of Trauma
2y 5m to grant Granted Mar 24, 2026
Patent 12569527
TETRASELMIS CHUII (T. CHUII) FOR THE TREATMENT OF MALE INFERTILITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564606
PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS
2y 5m to grant Granted Mar 03, 2026
Patent 12564551
Composition or oat extract comprising avenanthramide and ß-glucan
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
3y 0m
Median Time to Grant
High
PTA Risk
Based on 1058 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month